HEMOSTASEOLOGY

CRS has extensive experience in conducting clinical trials in hemostaseology – during the past several years we have accurately performed and successfully completed a wide variety of projects in blood coagulation. Our continuous work ranges from first-in-human (FIH) to Phase IIa studies in this exceptional field –– e.g., single ascending dose (SAD) and multiple ascending dose (MAD) studies, trials on drug-drug interaction (DDI), food-drug interaction (FDI), bioavailability (BA) and bioequivalence (BE).

CRS has comprehensive clinical research experience in this exceptional field

Blood coagulation and related processes are an up-to-date research field. The underlying mechanisms and interactions as well as new pharmacological interventions are targets for all kinds of clinical research and clinical trials.

With a broad and comprehensive experience in first-in-human and first-in-class studies, CRS is the perfect partner for any kind of such clinical trials. Besides our high quality with regard to all trial aspects CRS offers a high flexibility concerning all study types.

Our extensive experience makes us your right and reliable partner

In recent years CRS has performed diverse clinical trials in hemostaseology, investigating not only small molecules but antibodies as well. And we are highly experienced with various formulations for application, e.g., oral, intravenous (i.v.), subcutaneous (s.c.), inhalative, and nasal application, whereas injection or infusion can also be prepared weight adapted.

CRS guarantees highest quality at all levels

CRS offers a constant high-end quality of clinical trial data due to our “zero mistake” philosophy (see also our “VALUES” in the menu “WE ARE”). Furthermore, with our low employee fluctuation rate our clinical staff has long-time experience in all clinical trial procedures as well as in complex test methods for trials in hemostaseology, e.g., the determination of bleeding time.

The specialized CRS lab team ensures that a wide variety of samples is processed accurately and always on time. And – of course – we are consistently extending our medical diagnostic methods to offer you as our customer the best fit for your particular clinical trial.

  • Bleeding time (Surgicutt)
  • Bedside monitoring – activated partial thromboplastin time (aPTT) (Hemochron©)
  • Partial thromboplastin time with kaolin
  • Thrombocyte aggregation

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chief Medical Officer (CMO)
located at CRS Mannheim


LET’S TALK SCIENCE

Dr. Volker Menschik

Chief Business Officer (CBO)
located at CRS Berlin


LET’S TALK BUSINESS

BACK TO OVERVIEW

CRO Leadership Awards 2019

CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability.

European Biotechnology Guide

Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019.

EcoVadis – CSR Rating

Based on the CSR rating by EcoVadis in July 2018 CRS has been granted Silver Recognition Level.